Delta Financial Advisors LLC Sells 39,393 Shares of Pfizer Inc. (NYSE:PFE)

Delta Financial Advisors LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 66.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,293 shares of the biopharmaceutical company’s stock after selling 39,393 shares during the quarter. Delta Financial Advisors LLC’s holdings in Pfizer were worth $584,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Worth Asset Management LLC bought a new stake in shares of Pfizer in the 1st quarter valued at $29,000. Briaud Financial Planning Inc bought a new stake in shares of Pfizer in the 3rd quarter valued at $30,000. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new stake in Pfizer during the 3rd quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.4 %

Shares of Pfizer stock traded down $0.11 on Thursday, hitting $25.31. The stock had a trading volume of 17,223,956 shares, compared to its average volume of 42,223,680. The stock has a market cap of $143.32 billion, a price-to-earnings ratio of 70.61, a PEG ratio of 1.16 and a beta of 0.61. The stock’s 50-day simple moving average is $27.19 and its two-hundred day simple moving average is $28.76. Pfizer Inc. has a one year low of $25.26 and a one year high of $40.56. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. Finally, Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.